UBS O'Connor’s Soleno Therapeutics SLNO Stock Holding History

UBS O'Connor’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,000	Closed	-$40.2K	–	431
2025 Q2	$40.2K	Sell	12,000 -6,000	-33%	-$449K	﹤0.01%	331
2025 Q1	$450	Buy	+18,000	New	+$876K	﹤0.01%	322

Other funds holding SLNO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

UBS O'Connor's SLNO Position: Q3 2025 in Review

UBS O'Connor sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 10,362 shares — an estimated $868K sold.

UBS O'Connor first reported a position in SLNO in Q2 2024 and held it in 5 quarters. The position peaked at $1.22M in Q1 2025. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

UBS O'Connor reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 10,362 Soleno Therapeutics shares in Q3 2025, an estimated $868K.
UBS O'Connor first reported a position in Soleno Therapeutics in Q2 2024 and held it in 5 quarters.
UBS O'Connor's Soleno Therapeutics position peaked at $1.22M in Q1 2025.
240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.